Business Today

The Sweet Pill

Drug regulatory reforms in China have turned the heat on the Indian pharmaceutical industry and raised the cost of bulk drugs. But some firms have managed to turn the crisis into an opportunity by filling in the space left by the Chinese.

Ludhiana based IOL Chemical, the largest maker of ibuprofen active pharmaceutical ingredient (API) in the world with annual capacity of 12,000 metric tonnes, is in a sweet spot, a rarity these days in a segment such as API manufacturing, where China has taken a lead over India. "We are noticing shortage of products from China and rise in prices. This is a big opportunity for the companies in India to build global capacity to take advantage of the trend. For instance, we have over the past one year more than doubled our ibuprofen API capacity from 5,000 metric tonnes per annum to 12,000 metric tonnes," says Vijay Garg, Joint Managing Director, IOL. The company has "33 per cent world market share for the product as against 10 per cent a year ago,"

You’re reading a preview, subscribe to read more.

More from Business Today

Business Today2 min readFinance & Money Management
Regulatory Rap
THE RESERVE BANK of India (RBI) has a history of taking stringent regulatory action against financial institutions to safeguard customers’ interests. The latest step taken by the regulator is against Kotak Mahindra Bank, prohibiting it from onboardin
Business Today1 min read
Top Billing
THE AVERAGE CEO COMPENSATION IN INDIA HAS INCREASED TO ₹13.8 CRORE, NEARLY 40% HIGHER THAN THE PRE-PANDEMIC YEAR OF 2020 *WITH LONG-TERM INCENTIVES, MOSTLY PAID THROUGH SHARE-LINKED INCENTIVES; FIGURES IN BRACKETS INDICATE CAGR  SOURCE DELOITTE INDIA
Business Today3 min read
Fostering Pluralism
AXIS BANK, THE country’s third-largest private sector bank in terms of total assets, has been making significant strides not just in financial services but also in creating an inclusive and employee-friendly work environment. One of its key landmarks

Related